Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B1 | P14061 | 12/20 | 0.68 |
| ▸ | CYP19A1 | P11511 | 7/20 | 0.53 |
| ▸ | ESR1 | P03372 | 3/20 | 0.53 |
| ▸ | STS | P08842 | 2/20 | 0.51 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1237347 | 1.00 | HSD17B1 (0.68) | HSD17B1CYP19A1ESR1STSESR2 | |
| SCHEMBL12888928 | 1.00 | HSD17B1 (0.68) | HSD17B1CYP19A1ESR1STSESR2 | |
| SCHEMBL12888950 | 0.89 | HSD17B1 (0.72) | HSD17B1CYP19A1ESR1STSESR2 | |
| SCHEMBL1234800 | 0.89 | HSD17B1 (0.72) | HSD17B1CYP19A1ESR1STSESR2 | |
| SCHEMBL12888948 | 0.89 | HSD17B1 (0.72) | HSD17B1CYP19A1ESR1STSESR2 | |
| SCHEMBL12888897 | 0.87 | HSD17B1 (0.74) | HSD17B1CYP19A1ESR1STSESR2 | |
| SCHEMBL5000982 | 0.87 | HSD17B1 (0.74) | HSD17B1CYP19A1ESR1STSESR2 | |
| SCHEMBL12904411 | 0.84 | STS (0.51) | HSD17B1CYP19A1ESR1STS | |
| SCHEMBL12904595 | 0.84 | HSD17B1 (0.70) | HSD17B1CYP19A1ESR1STSESR2 | |
| SCHEMBL12888935 | 0.84 | HSD17B1 (0.70) | HSD17B1CYP19A1ESR1STSESR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7893284-B2 | Oestrogen derivatives as inhibitors of steroid sulphatase | STERIX LIMITED (GB) | 2011-02-22 | — | — | US | disclosed |
| EP-1608671-B1 | OESTROGEN DERIVATIVES AS INHIBITORS OF STEROID SULPHATASE | STERIX LTD (GB) | 2010-01-06 | — | — | EP | disclosed |
| US-20060094696-A1 | Oestrogen derivatives as inhibitors of steroid sulphatase | STERIX LIMITED (GB) | 2006-05-04 | — | — | US | disclosed |
| EP-1608671-A1 | OESTROGEN DERIVATIVES AS INHIBITORS OF STEROID SULPHATASE | Sterix Limited (GB) | 2005-12-28 | — | — | EP | disclosed |
| WO-2004085459-A1 | OESTROGEN DERIVATIVES AS INHIBITORS OF STEROID SULPHATASE | STERIX LIMITED (GB) | 2004-10-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060094696-A1 | Oestrogen derivatives as inhibitors of steroid sulphatase | HSD17B11, ESRRA, ESRRB | HSD17B1 21/4885CYP19A1 9/4885ESR1 6/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.